Zai Lab Q2 2026 revenue $106.3M, net loss $50.8M; pipeline advances with zoci and ZL-1503

Zai Lab Ltd

Total revenue $106.3M (down 3% YoY) but product revenue up 11% sequentially; net loss $50.8M ($0.46/ADS) vs $40.7M loss in Q2 2025.
R&D expenses rose to $61.8M (up 22% YoY) due to licensing fees; cash $717.5M as of June 30, 2026.
Zoci (DLL3 ADC) received FDA ODD for NECs and Fast Track for epNECs; Phase 1 data at ESMO 2026; registrational Phase 3 planned H2 2026.
ZL-1503 (IL-13/IL-31Rα) initial Phase 1 data expected H2 2026; KarXT launched in China; TIVDAK approved in China for cervical cancer.
VYVGART label expanded in US; partner Vertex's pove BLA accepted with PDUFA Nov 30, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.